Meropenem Qilu (Meropenem)

Meropenem Qilu is a broad‑spectrum carbapenem antibiotic used for severe infections caused by susceptible bacteria.

• Complicated intra‑abdominal infections: provides bactericidal activity to resolve intra‑abdominal sepsis.
• Complicated urinary tract infections: eradicates resistant Gram‑negative pathogens in the urinary system.
• Nosocomial pneumonia: treats hospital‑acquired lung infections caused by multidrug‑resistant organisms.
• Septicemia: rapidly clears bloodstream infections with high bacterial load.

• Meropenem inhibits bacterial cell wall synthesis by binding with high affinity to penicillin‑binding proteins (PBPs). This binding blocks the transpeptidation step of peptidoglycan cross‑linking, leading to weakened cell walls and osmotic lysis of susceptible Gram‑negative and Gram‑positive bacteria.

Adverse reactions may occur with meropenem therapy and should be monitored.

Common Side Effects

• Diarrhea: mild to moderate watery stools.
• Nausea: transient feeling of stomach upset.
• Rash: erythematous skin lesions.
• Elevated liver enzymes: transient increase in ALT/AST.
• Injection site pain: discomfort at the IV site.

Serious or Rare Side Effects

• Anaphylaxis: severe allergic reaction with airway compromise.
• Seizures: particularly in patients with renal impairment or CNS disorders.
• Clostridioides difficile colitis: severe diarrhea due to gut flora disruption.
• Thrombocytopenia: marked reduction in platelet count.
• Acute interstitial nephritis: renal inflammation presenting with impaired function.

Meropenem should be used with caution in specific clinical situations.

• Renal function monitoring: adjust dose in patients with impaired clearance.
• Hepatic function monitoring: observe liver enzymes during prolonged therapy.
• Allergy assessment: avoid in individuals with known carbapenem hypersensitivity.
• Neonates and children: use only under specialist guidance due to dosing variability.
• Concomitant valproic acid: may reduce serum valproate levels, risking seizure breakthrough.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Meropenem may interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid)

• Valproic acid: meropenem can markedly lower valproate concentrations, compromising seizure control.
• Probenecid: may increase meropenem plasma levels, raising risk of toxicity.

Moderate Interactions (Monitor Closely)

• Aminoglycosides: combined nephrotoxic potential; monitor renal function.
• Loop diuretics: may enhance ototoxicity when used together.
• Warfarin: possible alteration of INR; check coagulation parameters regularly.
• Antacids containing magnesium or aluminum: may reduce meropenem absorption if given orally, though IV route minimizes this effect.